Diseases [C] » Neoplasms
Description
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. MeSH
Hierarchy View
Subtype Terms (15)
Cysts
2 drugs (1 approved, 1 experimental)
Hamartoma
386 drugs (160 approved, 226 experimental)
Neoplasms by Histologic Type
45 drugs (27 approved, 18 experimental)
Neoplasms by Site
48 drugs (29 approved, 19 experimental)
Neoplasms, Hormone-Dependent
4 drugs (3 approved, 1 experimental)
Neoplasms, Multiple Primary
3 drugs (2 approved, 1 experimental)
Neoplasms, Second Primary
20 drugs (18 approved, 2 experimental)
Neoplastic Processes
2 drugs (1 approved, 1 experimental)
Neoplastic Syndromes, Hereditary
14 drugs (12 approved, 2 experimental)
Paraneoplastic Syndromes
1 approved drug
Precancerous Conditions
132 drugs (93 approved, 39 experimental)
Approved Indicated Drugs (17)
Phase 4 Indicated Drugs (133)
haploidentical mononuclear cells
human papillomavirus 9-valent vaccine, recombinant (Gardasil 9)
human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)
Phase 3 Indicated Drugs (238)
n-(4-hydroxyphenyl)all-trans retinamide
peripheral blood hematopoietic cell
Phase 2 Indicated Drugs (950)
[18f]fluoropivalate ([18f]fluoro-2,2-dimethylpropionic acid)
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
2-fluoropropionyl-labeled pegylated dimeric rgd peptide
4-demethyl-4-cholesteryloxycarbonylpenclomedine
adenovirus type-5 vectored covid-19 vaccine
allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
allogeneic gamma-delta t cells
allogeneic gm-csf-secreting breast cancer vaccine
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
alvac melanoma multi-antigen therapeutic vaccine
anti-ctla-4/pd-1 expressing egfr-car-t cells
anti-ctla-4/pd-1 expressing muc1-car-t cells
Antigen Peptide-specific DC-CTL Cells
anti-ley-car-transduced t cells
anti-minor histocompatibility complex (miha) donor t-lymphocytes
anti-ny eso-1 t cell receptor cd62l+ cells
anti-ny eso-1 t-cell receptor pbl
anti-p53 t-cell receptor-transduced peripheral blood lymphocytes
autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
autologous cytokine induced killer cells
autologous ebv specific cytotoxic t lymphocytes
autologous hematopoietic stem cells
autologous natural killer cells
autologous tumor infiltrating lymphocytes
autologous tumor lysate-pulsed d-cik
autologous umbilical cord blood
autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes
axicabtagene ciloleucel (Yescarta)
boronophenylalanine-fructose complex
brentuximab vedotin (adcetris)
carcinoembryonic antigen rna-pulsed dc cancer vaccine
cd44v6-specific car gene-engineered t cells
dendritic cells loaded with 17 antigens
fam-trastuzumab deruxtecan-nxki (Enhertu)
gadopenteate dimeglumine (magnevist)
haploidentical natural killer cell
hla-a*2402 or a*0201 restricted peptides
hla-mismatched donor peripheral stem cell infusion
human papillomavirus 16 monovalent
hyaluronidase (human recombinant) (hylenex)
hydroxychloroquine (plaquenil)
interferon alpha-2a (roferon-a)
interferon gamma-1b (actimmune)
invariant natural killer cells
in vitro-treated peripheral blood stem cell
in vitro tumor reactive, chimeric t cell receptor gene-transduced pbl
lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
mage-a1-specific t cell receptor-transduced autologous t-cells
masct:multiple antigens specific cellular therapy
muromonab cd3 (Orthoclone OKT3)
ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
pd-1 antibody expressing mesocar-t cells
pd-1 antibody expressing mesothelin specific car-t cells
pg13-mage-a3 tcr9w11 transduced autologous peripheral blood lymphocytes
pneumococcal 13-valent conjugate vaccine (prevnar 13)
serum-derived bovine immunoglobulin/protein isolate
super circulating tumor infiltrating lymphocytes
talimogene laherparepvec (Imlygic)
telomerase: 540-548 peptide vaccine
tgfbdnrii-transduced autologous tumor infiltrating lymphocytes
tumour infiltrating lymphocytes
Phase 1 Indicated Drugs (1788)
124i-iodo-azomycin galacto-pyranoside
4h11-28z/fil-12/efgrt+ genetically-modified t cells
5-aza-4'-thio-2'- deoxycytidine
68ga-1,4,7-triazacyclononane-n,n',n''-triacetic acid
7-t-butyldimethylsilyl-10-hydroxycamptothecin
adenovirus-mediated human interleukin-12
allogeneic human unmodified inkt
anti-egfr immunoliposomes loaded with doxorubicin
anti-macrophage migration inhibitory factor antibody
anti-ny eso-1 tcr-transduced t cells
autologous ad her2 dendritic cells
autologous apd-l1 armored anti-cd22 car t cells
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous dendritic cells loaded with autologous tumor lysate
autologous ebv-ctl transduced with vector sfg-cna12
autologous genetically modified afpc332 t cells
autologous mesenchymal stem cells
autologous ny-eso-1-specific cd8-positive t lymphocytes
av0113 dendritic cell cancer immune therapy
azurin-derived cell-penetrating peptide p28
bcl-2 antisense oligonucleotide
bone marrow derived mesenchymal stem cells
camptothecin-20-o-propionate hydrate
car-nk cells targeting nkg2d ligands
cd20/cd22 targeted car t-cells
cngrc peptide-tnf alpha conjugate
colloidal gold-bound tumor necrosis factor
cytomegalovirus ie-1-specific cytotoxic t lymphocytes
cytomegalovirus pp65-specific cytotoxic t lymphocytes
dl-2-(difluoromethyl) ornithine
egfrbi-armed autologous activated t cells
ga-68labeled f(ab') 2- trastuzumab
her2bi-armed activated t cells
human fecal microbiota (Reybota)
levorphanol tartrate (levo-dromoran)
live attenuated influenza virus vaccine (flumist)
lutetium dotatate lu-177 (Lutathera)
mage-a4 tcr gene-modified t cells
mem-288 intratumoral injection
methylthiovinblastine dihydrochloride
mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes
modified vaccinia virus ankara vaccine expressing p53
multi-virus-specific cytotoxic t lymphocytes
mvf-her-2(628-647)-crl 1005 vaccine
neoantigen-expanded cell therapy.
ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine
procaspase activating compound-1
recombinant adenovirus-hifn-beta
recombinant fowlpox-b7.1 vaccine
recombinant fowlpox-cea(6d)/tricom vaccine
recombinant human il12/15-pdl1b oncolytic hsv-1 injection (vero cell))
recombinant vesicular stomatitis virus-expressing interferon-beta
ror1 car-specific autologous t-lymphocytes
sirna-transfected peripheral blood mononuclear cells apn401
sterile compound c31510 for injection
tetra-o-methyl nordihydroguaiaretic acid
triciribine phosphate monohydrate
triethylenetetramine (trientine)
tumor associated antigen lymphocytes
tumor specific antigen induced cytotoxic lymphocyte
umbilical cord mesenchymal stem cells
vaccinia-cea(6d)-tricom vaccine
y90 dota anti-cea monoclonal antibody m5a
Other Experimental Indicated Drugs (130)
ga-68-dota-toc (Ga-68-dota-toc)
gadofosveset trisodium (ablavar)
Organization Involved with Phase 4 Indications (75)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
Chinese Academy of Medical Sciences
Instituto Mexicano del Seguro Social
Institutul Clinic Fundeni, Bucarest, Romania
National Institute for Tuberculosis and Lung Diseases, Poland
Saint-Petersburg State Medical University
Shenzhen SiBiono GeneTech Co.,Ltd
Organization Involved with Phase 3 Indications (225)
Academic and Community Cancer Research United
Advanced Accelerator Applications
Albert Einstein Israelite Hospital
All India Institute of Medical Sciences
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Arbeitsgemeinschaft medikamentoese Tumortherapie
Badalona Hospital Germans Trias i Pujol
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
BioNumerik Pharmaceuticals, Inc.
Blokhin's Russian Cancer Research Center
Blueprint Medicines Corporation
Canadian Institutes of Health Research (CIHR)
Cancer and Leukemia Group B (CALGB)
Celilo Cancer Center at Mid-Columbia Medical Center
Children's Cancer and Leukaemia Group
Chinese Society of Lung Cancer
City of Hope National Medical Center
Clinical Research Technology S.r.l.
Danish Breast Cancer Cooperative Group
Dutch Health Care Insurance Board
Eastern Cooperative Oncology Group
Epidemiological and Clinical Research Information Network
European Organisation for Research and Treatment of Cancer
Guangzhou Bioseal Biotechnology Co., Ltd.
Herbert Irving Comprehensive Cancer Center
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Italian Association for Pediatric Hematology Oncology
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Krankenhaus der Barmherzigen Schwestern Linz
Medical Enterprises Europe B.V.
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Nursing Research (NINR)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
Nordic Society for Gynaecologic Oncology
OncoQuest Pharmaceuticals Inc.
Oregon Health and Science University
People's Liberation Army of China
Radiation Therapy Oncology Group
St. Antonius Hospital, Nieuwegein
The Canadian Blood and Marrow Transplant Group
The Scientific and Technological Research Council of Turkey
Universidad Autonoma de Barcelona
University of Alabama, Birmingham
University of California, Irvine
University of California, Los Angeles
University of California, San Francisco
University of Rome Tor Vergata
University of Southern California
University of Southern Denmark
William Osler Health Service Brampton
Winnipeg Regional Health Authority
Xiamen Amoytop Biotech Co., Ltd.
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 2 Indications (600)
Acetylon Pharmaceuticals Incorporated
AIDS and Cancer Specimen Resource
Australasian Gastro-Intestinal Trials Group
Azienda Ospedaliera San Gerardo di Monza
Beijing InnoCare Pharma Tech Co., Ltd.
Big Ten Cancer Research Consortium
BioMed Valley Discoveries, Inc
British Columbia Cancer Agency
Canadian Society of Hematology
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Case Western Reserve University
Catholic University of Sacred Heart, Rome
Centre Georges Francois Leclerc
Centre Hospitalier La Source, Orleans
Cheil General Hospital & Women's Healthcare Center
Chengdu Shi Endor Biological Engineering Technology Co., Ltd
Children's Medical Center Dallas
Ciusss de L'Est de l'Île de Montréal
Coastal Connecticut Research, LLC
Collaborative Ependymoma Research Network
Department of Radiation Oncology
Detroit Clinical Research Center
